Current Practices in the Use of Anti-Mullerian Hormone for Surveillance of Ovarian Function in Childhood Cancer Survivors: A Report from the Pediatric and Adolescent Committee of the Oncofertility Consortium.
Document Type
Article
Publication Date
2025
Publication Title
J Adolesc Young Adult Oncol
Abstract
Purpose: Anti-Mullerian hormone (AMH) is a surrogate measure to assess ovarian reserve in childhood cancer survivors, but consensus is lacking on when to obtain and how to use AMH data.
Methods: Pediatric and adolescent committee (PAC) members of the Oncofertility Consortium were invited by email to complete a survey regarding ovarian reserve surveillance and their use of AMH. Responses were collected through REDCap, and results were stratified by specialty: pediatric oncology and endocrinology (PED) or adult/pediatric gynecology and reproductive endocrinology (GYN). Descriptive statistics and Fisher's exact tests were used for analysis using SAS v9.4.
Results: Surveys were completed by 48 of 123 eligible PAC members (28 PED, 19 GYN, response rate 39%). The majority (83.3%) reported using AMH as a measure of ovarian reserve, with the earliest timepoint to begin AMH surveillance to be 12-23 months from therapy completion (63%). While most respondents felt the benefits of testing outweighed the limitations (78.7%), commonly reported limitations included variability of results (60.4%) and lack of standardization in use of AMH (52.1%). Differences between PED and GYN respondents included how AMH was used among their clinical practice and the timing of laboratory evaluation.
Conclusions: Most respondents indicated they used AMH; however, practices in its application varied depending on specialty backgrounds. Evidence-based clinical practice guidelines would improve the standardization of surveillance and counseling and prevent missed opportunities for fertility preservation in survivorship.
Recommended Citation
Bjornard K, Close A, Rios J, Anazodo A, Levine J, Yu C, et al. Current practices in the use of anti-mullerian hormone for surveillance of ovarian function in childhood cancer survivors: A report from the Pediatric and Adolescent Committee of the Oncofertility Consortium. J Adolesc Young Adult Oncol. 2025. Epub 2025/07/14. doi: 10.1177/21565333251359617. PMID: 40658204.
DOI
10.1177/21565333251359617
ISSN
2156-535X
PubMed ID
40658204
Comments
Helen DeVos Children's Hospital